Pneumococcal Brands

Merck's 23-valent pneumococcal polysaccharide vaccine (PPSV23), FDA approved in 1983 as an expansion of Merck's 14-valent formulation licensed in 1977, providing T-cell independent immune protection against 23 pneumococcal serotypes in adults aged 50 and older and high-risk individuals, now used alongside conjugate vaccines per updated CDC recommendations.

Pfizer's pneumococcal conjugate vaccine franchise, originally developed by Wyeth as Prevnar (PCV7, FDA approved February 17, 2000), succeeded by Prevnar 13 (PCV13, FDA approved February 24, 2010) and Prevnar 20 (PCV20, FDA approved June 8, 2021), one of the world's best-selling vaccines with peak annual revenues exceeding $6 billion.